Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops cancer therapies. Its two FDA-approved medicines are Revuforj (revumenib), an oral menin inhibitor for certain forms of relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a CSF-1R-blocking antibody for chronic graft-versus-host disease after at least two prior lines of systemic therapy. Syndax sells Revuforj in the United States and co-commercializes Niktimvo there with Incyte, which leads axatilimab’s global commercialization. Syndax also studies revumenib in combination with standard therapies for acute leukemia and explores its use in myelofibrosis. Axatilimab is in clinical development for newly diagnosed chronic graft-versus-host disease and idiopathic pulmonary fibrosis. The company licenses the global rights to revumenib and axatilimab. It also holds a license for entinostat, whose development it has deprioritized, and has licensed rights to develop and commercialize entinostat in China and certain other Asian countries to Eddingpharm. Syndax is headquartered in New York, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R
Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.
Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning SNDX (Syndax Pharmaceuticals Inc). Coverage has skewed bullish: 3 bullish, 3 neutral, and 2 bearish.
Recent SNDX coverage spans earnings, market movers and financial news.
In the last 30 days, SNDX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($114K). The most active reporter was Podlesak Dennis with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong revenue growth and expanding patient base suggest continued upside for Syndax.
The CFO transition may influence Syndax's financial strategy and capital allocation, but no immediate price catalyst is evident.
Strong quarterly revenue growth and expanding patient base suggest upward price pressure.
Earnings and management commentary are likely to drive near-term repricing, as the market balances Revuforj adoption against the IPF setback and profitability timeline.
The award validates Syndax's drug and may improve market perception.
AlphAI scores every news story that mentions SNDX with an AI model for sentiment and relevance, and aggregates insider trades from Syndax Pharmaceuticals Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R
2 min readSyndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.
1 min readSyndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.
2 min readSyndax Pharmaceuticals (SNDX) reports Q3 earnings with analysts expecting a loss of $0.48 per share on revenue of $82.4M, up 79.5% YoY. Revenue growth is driven by Revuforj, its menin inhibitor for AML. Despite a recent clinical trial setback, all 12 analysts maintain Buy ratings with a $37.27 price target. Investors will focus on Revuforj's revenue trajectory and path to profitability.
6 min readSyndax Pharmaceuticals (SNDX) announced that its leukemia drug, Revuforj, won the Galien Foundation's Best Product for Rare/Orphan Diseases of 2026. Revuforj is approved for adults and children with relapsed or refractory acute leukemia, including those with NPM1 mutations or KMT2A translocations. The drug is the first and only menin inhibitor approved for these conditions. The Galien Foundation's award recognizes biomedical research and innovation.
3 min readSyndax Pharmaceuticals (SNDX) will report Q3'26 earnings on November 2. Analysts expect $81.75M revenue and a loss of $0.49 per share, according to estimates.
1 min readSyndax Pharmaceuticals' (SNDX) average price target was reduced from $37.55 to $37.27 by 11 analysts, with a range of $23 to $57. This implies a 125% upside from the Oct. 12 closing price. All 12 covering analysts maintain a 'Buy' rating.
1 min readCitigroup (NYSE:C) reported Q3 earnings of $2.85 per share, beating estimates. Bumble (NASDAQ:BMBL) surged 56% after a buyout deal. BIO-Key (NASDAQ:BKYI) rose 139% on a government security contract. Fermi (NASDAQ:FRMI) gained 21% on a credit agreement. Pershing Square (NYSE:PS) fell 11% after a downgrade. Cipher Digital (NASDAQ:CIFR) dropped 14% on a convertible notes offering. Syndax (NASDAQ:SNDX) declined 17% after a trial failure. Oil rose 0.4% to $94.13, while gold and silver fell.
7 min readUS futures mixed; Nasdaq lags as AI sector rout spreads from Wall Street to Asia, with Kospi down 7%. JPMorgan's FICC revenue misses estimates but raises NII forecast. Premarket: AAPL +0.7%, MSFT +0.4%, NVDA -0.7%. UNH rises 2% on raised guidance; SNDX plunges 10% on trial failure. 10Y yields down 5bps to 5.19%.
7 min readSyndax Pharmaceuticals (SNDX) shares fell 17.2% to $13.70 in pre-market trading after its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint. Other stocks moving lower include BioNTech (BNTX), down 6.1% to $90.01, and Seagate (STX), down 5.7% to $710.10, among others.
3 min read
